The Pfizer-BioNTech Covid-19 vaccine was administered at an advanced living facility in Worcester, Pennsylvania, USA on Wednesday, August 25, 2021.
Hannah Bell | Bloomberg | Getty Images
On Wednesday, a highly anticipated American study showed that Johnson & Johnson Covid-19 vaccinators are best given booster shots from Pfizer or Moderna.
The National Institutes of Health’s “mix and match” Covid vaccine study included more than 450 adults who received one of the three options currently available in the United States: Johnson & Johnson, Moderna, or Pfizer. The study looked at whether there are any advantages or disadvantages to using different boosters, and has not been peer-reviewed.
Volunteers were divided into groups and received additional original vaccine injections or boosters from different companies. Antibody levels were measured two and four weeks after the booster was given.
All combinations increased antibody levels, but the boosters from Pfizer and Moderna seemed to work best. According to this study, people who received booster doses of Moderna or Pfizer vaccine had a higher frequency of increased antibody response compared to people who received additional doses of Johnson & Johnson vaccine.
Studies have shown that recipients of Moderna or Pfizer’s original vaccine can easily switch to the third dose; the results are about the same. Volunteers who were initially vaccinated with Johnson & Johnson seemed to get a better immune response if they were vaccinated with boosters made by Pfizer or Moderna.
The researchers said there were no serious side effects associated with the additional injections, and no new symptoms appeared after receiving the booster injections. Two participants vomited behind their boosters, one received Moderna and the other received Johnson & Johnson. Two other people who received Johnson’s boosters reported fatigue or insomnia.
The researchers wrote in the study: “These data show that if the vaccine is approved or authorized as a booster, regardless of the main Covid-19 vaccination regimen, there will be an immune response.” They added: “Allogeneic immune enhancement strategies It may provide immunological advantages to optimize the breadth and longevity of protection achieved by currently available vaccines.”
Johnson & Johnson’s single-dose vaccine uses adenovirus, while Pfizer and Moderna’s two-dose vaccines use mRNA technology. The idea of some scientists is that by “mixing and matching” vaccines on different platforms, people may be able to obtain broader protection against the coronavirus and its new variants.
The results of the survey announced on Wednesday are expected to be announced at the meeting of the Food and Drug Administration’s Vaccine Advisory Committee on Friday.
Last month, U.S. regulators authorized Pfizer and BioNTech vaccines’ Covid booster injections to a wide range of Americans, including the elderly, adults with underlying diseases, and those who work or live in high-risk environments such as health And grocery workers.
This is a story of development. Please check for updates.
If you want to know more about business please go to https://updatednews24.com/category/business/